Impact of Elexacaftor/Tezacaftor/Ivacaftor on Healthcare Resource Utilization and Associated Costs Among People With Cystic Fibrosis in the US: A Retrospective Claims Analysis.

Michael S SchechterNatalia Sabater-AnayaGerry OsterDerek WeyckerHongsheng WuEmilio Arteaga-SolisSukirti BagalLisa J McGarryKate Van BruntJessica Morlando Geiger

Published in: Pulmonary therapy (2023)

These findings suggest that ELX/TEZ/IVA reduces the burden and costs associated with PEx and hospitalizations in people with CF.

Keyphrases

cystic fibrosis
healthcare
health insurance
health information
social media